20 April 2026
20 April 2026
In this issue: CDMOs use of digital twins to realise a strategic advantage, Physical AI's rise in pharma manufacturing, and more.
UCB will pay $650m upfront and up to $500m in future milestones.
The order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.
The biotech will primarily focus on taking the oral and injectable form of its lead candidate, ribupatide, through late-stage obesity trials.
Enflonsia is contraindicated in infants with hypersensitivity to its active substance or excipients.
The regulator requires Lilly to evaluate the “unexpected serious” risks associated with Foundayo.
Cochrane’s research looked at 17 clinical trials of anti-amyloid drugs in Alzheimer’s disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
